Udupi: Sea erosion damages concrete road near Padukere

Bengaluru, Apr 9: 10 new positive cases have been confirmed in Karnataka, apart from the recent fatality of an 80-year-old woman from Gadag district, the health department said on Thursday.

The fresh cases have been reported in the state from last evening to Thursday noon.

Till date, 191 COVID-19 positive cases have been confirmed, which includes 6 deaths and 28 discharges, the update said.

Among the 10 positive cases, eight are contacts of patients who have already tested positive- one each from Belagavi, Mandya and Chikkaballapura, two from Mysuru, and three from Bagalkote; while two from Bengaluru city are with a travel history to Delhi.

Three cases from Bagalkote are children- two boys of 4 and 13 years of age, and one girl of 9 years old.

The elderly woman died on April 8 in Gadag, the department said in its mid-day situation update.

Confirming that her reports tested positive on April 7, officials had said, she had a history of Severe Acute Respiratory Infection (SARI).

Bengaluru, May 22: Karnataka government on Thursday said that there will be no inter-district check-posts for health screening in the State.

"There will be no inter-district check-posts for health screening in the State. Any health screening for passengers travelling by public transport -- buses and trains -- will be done at the origin of the journey and all those passengers found asymptomatic will be allowed to travel," reads the statement issued by the Commissionerate of Health and Family Welfare Services.

It further reads: "The agencies running public transport (KSRTC and others, Indian Railways, private bus operators) should ensure health screening of passengers before the start of the journey. There will be no health screening of passengers travelling by private vehicles across districts in Karnataka." 

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.